How much cash does Emergent Biosolutions generate?

Emergent Biosolutions (EBS) generated $150.3M in operating cash flow over the trailing twelve months.

What is Emergent Biosolutions's free cash flow?

After $12.6M of capital expenditures, Emergent Biosolutions's free cash flow was $141.1M over the trailing twelve months, up 310.0% year over year.

Where does Emergent Biosolutions's cash flow data come from?

Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Emergent Biosolutions EBS Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	$75.9M+136%	$139.5M+124%	-$131.6M+76.7%
Depreciation and amortization	$93.9M-11.7%	$95.8M-11.9%	$98.3M-12.5%	$101.3M-11.1%	$106.3M-10.2%
Stock-based compensation	$16.6M+22.1%	$16.2M-10.0%	$15.2M-14.1%	$12.7M-34.5%	$13.6M-38.7%
Deferred income taxes	——	——	——	——	——
Amortization of debt issuance costs	$9.3M—	$9.8M—	$9.4M—	——	——
Gain (loss) on sale of assets	-$5M—	-$4.5M—	——	——	——
Change in accounts receivable	-$59.9M—	-$25.5M—	$103.5M—	-$50.4M—	——
Change in inventories	——	——	——	——	——
Change in accounts payable	——	——	-$30M—	-$49M—	-$36M—
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	——	-$52.8M+72.1%	-$199.1M-1,852%
Other working capital changes	——	——	——	——	$1.7M-85.2%
Change in deferred revenue	$8.7M—	$5.2M—	-$400K—	——	——
Change in income taxes payable/receivable	——	——	——	——	——
Net cash from operating activities	$150.3M—	$172.9M—	——	——	——
Capital expenditures	$12.6M-19.7%	$13.8M-39.7%	$11.6M-64.4%	$14M-64.5%	$15.7M-66.8%
Proceeds from sale of property, plant and equipment	——	——	——	$46.1M—	$46M—
Net cash from investing activities	——	——	——	$217.3M—	$195.5M—
Repurchases of common stock	$33.9M—	$24.9M—	$15.8M—	$6.9M—	——
Proceeds from issuance of common stock	$400K—	$0—	$1M+400%	$800K+300%	$0-100%
Taxes paid for net share settlement	$3.7M+185%	$1.4M+16.7%	$1.3M+30.0%	$1.3M+62.5%	$1.3M+62.5%
Net cash from financing activities	-$147.6M+36.3%	-$136.6M+28.3%	-$22.7M+88.1%	-$187.1M-252%	-$231.6M+52.7%
Effect of exchange rate changes on cash	——	——	——	$300K+175%	-$700K+30.0%
Net increase (decrease) in cash	——	——	——	$200M+582%	$73.8M+120%
Interest paid	$46.1M-22.1%	$49.7M-22.3%	$49.9M-26.2%	$52.8M-19.4%	$59.2M-13.2%
Income taxes paid	$30.8M—	$40M—	——	——	——
Amortization expense related to capitalized debt issuance costs	$9.3M—	$9.8M—	$9.4M—	——	——
Gain (Loss) on Disposition of Assets	-$5M+82.9%	-$4.5M+84.4%	-$3.5M+90.3%	-$14.3M—	-$29.2M—
Accrued compensation and employee benefits	——	——	——	——	——
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable	——	——	——	——	——
Long-term incentive plan accrual	$2.7M-15.6%	$3.1M-13.9%	$3.4M-5.6%	$3.3M-23.3%	$3.2M-46.7%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	-$52.8M+72.1%	-$199.1M-1,852%
Other Noncash Income (Expense)	——	——	——	——	$1.7M-85.2%
Payments For (Proceeds From) Contingent Consideration Liability (Asset), Investing Activities	——	——	——	-$80M-2,640%	-$60M-1,370%
Payments to notes receivables	——	——	——	——	$5M—
Proceeds from disposals of property, plant and equipment	——	——	——	$46.1M—	$46M—
Payments Of Debt Extinguishment Costs	——	$3.8M—	$2.85M—	$1.9M—	$950K—
Proceeds from exercises of stock options and other stock issuances	-$100K-106%	$0-100%	$800K-33.3%	$1.6M+33.3%	$1.6M-11.1%
Accrued payables for capital expenditures	——	——	——	——	——
Fair Value Adjustment Of Warrants	——	——	——	——	-$8.4M—
Increase Decrease In Contract With Customer Liability	$8.7M—	$5.2M—	-$400K—	——	——
Free cash flow	$141.1M—	$162.5M—	——	——	——
Free cash flow	$141.1M—	$162.5M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Emergent Biosolutions.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Emergent Biosolutions generate?: Emergent Biosolutions (EBS) generated $150.3M in operating cash flow over the trailing twelve months.
What is Emergent Biosolutions's free cash flow?: After $12.6M of capital expenditures, Emergent Biosolutions's free cash flow was $141.1M over the trailing twelve months, up 310.0% year over year.
Where does Emergent Biosolutions's cash flow data come from?: Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.